The emerging 3D biology field uses human model systems like organoids to revolutionize drug discovery and our understanding of disease.
Pioneering a new future of drug discovery rooted in 3D biology will empower researchers to personalize therapies, reduce a medicine’s time to market, and enhance quality of life for patients around the world.
Molecular Devices has been a life sciences industry leader for 40 years. We believe in the revolutionary promise of 3D cell models to advance next generation drug discovery. Whether you’re making the transition from 2D to 3D cell culture for the first time, scaling your organoid development program, or integrating a fully-automated screening workflow, we’re here to help.
Our robust portfolio of end-to-end high-throughput solutions, user-friendly AI-powered data analysis, and committed 3D biotechnology investments, will support you in overcoming all your 3D biology challenges, starting with:
Provision of large batches of standardized assay-ready organoids
Scale in-house organoid and 3D tissue development with an automated bioprinter, high-content imager, and AI-powered image analysis software.
Streamline end-to-end workflows with next-gen 3D biology technologies that are customized into a fully-integrated, automated setup for any lab and supported by machine learning-enabled data analysis solutions.
Our specialized team of automation engineers and PhD-level scientists offer services from consultation to implementation. We take time to understand your application process and biological requirements to customize a solution that fits your research needs — one that delivers reproducible results, by verifying optimal performance in-house prior to installation in your lab — helping safeguard your investment with proof of concept and validation services.
We believe organoids are the future of next-gen drug discovery, offering revolutionary promises to reduce drug development timelines, overcome limitations of conventional cell models, and move us away from animal research.
Are you ready to transition from 2D to 3D biology, but not sure where to start? In our latest blog, we show you what it takes to enter into this new drug discovery paradigm.
Growing organoids manually can present significant challenges for researchers that delay experiments and increase costs. Most common is an inability to produce sufficient numbers of organoids that are homogeneous in quality and size. Batch-to-batch consistency is virtually impossible without the standardized, repeatable processes employed in a regulated, industrial environment.
Molecular Devices has global leadership in the scale-up and industrial manufacturing of human-derived 3D organoids. Facilitated by our unique, patent-pending bioprocess, our semi-automated procedure uses controlled, monitored conditions to produce large numbers of standardized PDOs within a defined size range. Rigorous quality control ensures reduced batch-to-batch and user-to-user variability.
BioAssemblyBot® 400 (BAB400) by Advanced Solutions is an intelligent robot for drug discovery that includes specific enhancements to Advanced Solutions’ existing bioprinting platform to help life scientists overcome the challenges of reproducing consistent, complex organoid models at scale for drug development. Out-of-the-box integration of the BAB400 with Molecular Devices’ ImageXpress® Cellular Imaging Systems enables turnkey automation of cell health monitoring and end-point assays.
In a fully automated enclosure, BAB400’s six-axis robotic arm uses a wide range of interchangeable hands to systematically reproduce organoids, while the ImageXpress Confocal HT.ai system and machine learning analysis inform the modeling and screening process with high-content cellular imaging information for increased precision.
The new Organoid Innovation Center at Molecular Devices combines cutting-edge technologies with novel 3D biology methods to address key challenges of scaling complex 3D biology.
The collaborative space brings customers and researchers into the lab to test automated workflows for organoid culturing and screening with guidance from in-house scientists.
An end-to-end solution standardizes the organoid development process with cell culture, treatment, and incubation, through to imaging, analysis, and data processing, delivering consistent, unbiased, and biologically-relevant results at scale.
Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce
Molecular Devices expands global R&D hub in Austria
Molecular Devices and HeartBeat.bio announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery
Molecular Devices continues investment in Organoid Innovation Center adding cell engineering capabilities to automated 3D cell culture platform
Molecular Devices opens Organoid Innovation Center